Boiron expands its range of homeopathy medicines in India

Image
IANS Kolkata
Last Updated : Oct 04 2018 | 6:10 PM IST

Boiron Laboratories, the Indian subsidiary of homeopathic medicines maker Boiron S.A. (France), is expanding its presence in the country and is in the process of registering its proprietary products, an official said here on Thursday.

"We had launched 480 medicines in July, 2017 and recently expanded our range introducing 150 high potency standardised homeopathic medicines in India. This expansion process will continue. We are in the process of registering our proprietary products," company's Managing Director Prashant Surana told reporters here.

The company is keen on introducing more brands in India, however, the main challenge is that "currently the branding of single-ingredient products is not allowed".

"This prevents Boiron from introducing many of the global brands such as Oscillococcinum, which is the bestselling homeopathy brand for cold and flu management around the world," he said.

"All the ailments can be covered but we will set our launching priorities based upon market needs with innovative dispensing forms," he said.

According to him, the market size for homeopathy medicines in India is currently over Rs 1,000 crore, which has been growing by 15-20 per cent annually.

For the first time, medicines from USFDA approved homeopathy manufacturing plants are available in sealed multidose tubes and single dosage tubes across India, the company claimed.

The homeopathy major is currently importing drugs from France and will evaluate setting up a plant in India as the market develops.

"At one point in time, local manufacturing will become a necessity and be beneficial for our overall development in India. This could be our first major investment, others could follow thereafter. We have good reasons to believe this could happen in the near future," said Michele Boiron, Director, Boiron France.

The homeopathy major has five production facilities, 20 distribution platforms and presence in 50 countries.

--IANS

bdc/mag/sed

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 04 2018 | 6:00 PM IST

Next Story